Oral Solid Dose At Scale: Winning Strategies For Commercial Manufacturing Leaders

Scaling oral solid dose products now means handling HPAPIs, niche formulations, and modified-release designs that legacy processes were never built for. This e-book argues that the costliest problems are rarely operational. They are strategic decisions made early and revisited too late. It examines three persistent risks: formulations that fail at scale, regulatory exposure around HPAPI handling, and infrastructure or technology gaps that delay market entry. Along the way, it works through decision scenarios with trade-offs for each option, an audit-readiness checklist for HPAPI programs, and criteria for judging whether a CDMO fits a program beyond its stated capabilities. It also considers how early development choices shape what is possible after launch.

Explore the strategies and see how they apply to your own commercial programs.